title: [Levodopa intestinal infusion therapy in Parkinson's disease].
abstract: Medical treatment of advanced Parkinson disease complicated with fluctuations and dyskinesias remains difficult or in some patients totally ineffective. Recently, new methods were introduced to manage those problems: deep brain stimulation, subcutaneous apomorphine infusion and the Duodopa system for intrajejunal continuous delivery of gel containing levo-dopa/carbidopa (through percutaneous gastrostomy). This last method was proven to be very effective in reducing the fluctuations of levodopa plasma levels and furthermore in reducing the off periods and dyskinesias. The Duodopa system is used in patients with contraindications to deep brain stimulation or apomorphine infusions. According to recently published studies, it may also be more effective in reducing motor complications than other methods. The authors present the current knowledge on the Duodopa system, its effectiveness (also in relationship to other methods, specially deep brain stimulation and apomorphine) and possible complications (mostly due to gastric tube failures) along with the indications and contraindications.
authors.affiliation: Zakłd Pielêgniarstwa Neurologiczno-Psychiatrycznego, Wydział Nauk o Zdrowiu, Gdański Uniwersytet Medyczny, Szpital Specjalistyczny oew. Wojciecha, Al. Jana Pawła II 50, 80-462 Gdańsk. jaroslawek@gumed.edu.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Sławek
authors.forename: Andrzej
authors.initials: A
authors.lastname: Bogucki
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage*; D002230:Carbidopa / Q000008:administration & dosage*; D015259:Dopamine Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004386:Duodenum; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D006801:Humans; D007260:Infusion Pumps; D007980:Levodopa / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D002230:Carbidopa